Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 10/20 | 0.50 |
| ▸ | CA2 | P00918 | 10/20 | 0.50 |
| ▸ | CA9 | Q16790 | 8/20 | 0.50 |
| ▸ | CA12 | O43570 | 7/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | PPM1B | O75688 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12889180 | 1.00 | CA1 (0.50) | CA1CA2CA9CA12ALDH1A1 | |
| SCHEMBL11946139 | 1.00 | CA1 (0.50) | CA1CA2CA9CA12ALDH1A1 | |
| SCHEMBL6871204 | 1.00 | CA1 (0.50) | CA1CA2CA9CA12ALDH1A1 | |
| SCHEMBL17407788 | 1.00 | CA1 (0.50) | CA1CA2CA9CA12ALDH1A1 | |
| SCHEMBL15927849 | 1.00 | CA1 (0.50) | CA1CA2CA9CA12ALDH1A1 | |
| SCHEMBL1933648 | 0.88 | CA1 (0.42) | CA1CA2CA9CA12PPM1B | |
| SCHEMBL12855791 | 0.88 | CA1 (0.42) | CA1CA2CA9CA12PPM1B | |
| SCHEMBL12035199 | 0.88 | CA1 (0.42) | CA1CA2CA9CA12PPM1B | |
| SCHEMBL12855820 | 0.88 | CA1 (0.42) | CA1CA2CA9CA12PPM1B | |
| SCHEMBL1536108 | 0.87 | CA1 (0.41) | CA1CA2CA9CA12PPM1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7521445-B2 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2009-04-21 | — | — | US | disclosed |
| US-20070161641-A1 | Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161641-A1 | Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | DRD3, DRD2, HTR3C | CA1 4528/4885CA2 4676/4885CA9 4736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.